The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 28, 2022

Filed:

Mar. 07, 2017
Applicants:

Universitat Zurich, Zurich, CH;

Universitat Basel, Basel, CH;

Inventors:

Osiris Marroquin Belaunzaran, Zurich, CH;

Ulf Petrausch, Zurich, CH;

Christoph Renner, Zurich, CH;

Assignees:

UNIVERSITAT ZURICH, Zurich, CH;

UNIVERSITAT BASEL, Basel, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); C07K 14/74 (2006.01); A61P 37/02 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1774 (2013.01); A61P 35/00 (2018.01); A61P 37/02 (2018.01); C07K 14/70539 (2013.01); C07K 2319/30 (2013.01);
Abstract

The invention relates to a HLA-B57 open conformer or a HLA-B57 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B57 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B57 Fc open conformer and immune checkpoint inhibitors and/or checkpoint agonist agents. Furthermore, the invention relates to the use of HLA-B57 open conformer as an immunomodulator, particularly in diseases where modulation of diverse immune cell components (e.g. cytotoxic CD8+ T cells, Tregs) is a therapeutic strategy, e.g. infectious diseases.


Find Patent Forward Citations

Loading…